Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT07031427
Starting soon Observational

Incidence of Slow Delta EEG Frequencies (0.1-1 Hz) Before Burst Suppression

NCT07031427 · tracked via the Priya Life Science Switzerland tracker
Phase
Observational
Started
2025-07-01
Last updated
2025-06-27

Condition(s) studied

Burst SuppressionAnesthesia

Study summary

The electroencephalogram (EEG) measures brain waves during general anaesthesia via an electrode placed on the forehead. These brain waves show the different stages of natural sleep as well as the state of the brain when a patient is put under general anaesthesia for an operation. In this research project, the investigators aim to find out if the EEG signal shows slow wave activity (where an EEG wave repeats every 10 to 1 seconds) just before the onset of the burst suppression pattern, where the EEG waveform alternates between very small (suppression) and very large (burst) signals over a period of a few seconds. It is not currently known if and how often this occurs, but if it does, it would be a useful signal to help anaesthetists administer just the right dose of anaesthesia to patients.

Eligibility

Sex
ALL
Min age
60 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * patients undergoing elective general anaesthesia, and * aged 60 or above, and * have a good comprehension of German, and * require a general anaesthesia length of at least 1 hour (to ensure that we can record enough good quality EEG signal). Exclusion Criteria: * patients undergoing head or neck surgery or surgery in prone or lateral decubitus position (due to the limited placement space on the forehead required for the two EEG electrode systems, limited access to the forehead during surgery), or * patients undergoing emergency surgery, operations only requiring local or regional anaesthesia with sedation, or * patients who cannot follow procedures, or have an inability to give consent, or * known participation in another human research project (ClinO/HRO) that may affect the objectives of this study.

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Hirslanden Clinic Aarau Aarau Aagrau
Cantonal Hospital of Aarau Aarau Canton of Aargau

More Insel Gruppe AG, University Hospital Bern trials in Switzerland

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07031427 on ClinicalTrials.gov ↗ ← All trials in Switzerland